Supported by the grants of the National Natural Science Foundation of China(No.30872591);Shanghai Science and Technology Commission(No.02.04.11.006)
Objective: The aim of the study was to compare the hematologic toxicity of gemcitabine between fixed-dose rate (FDR) infusion and 30-minute standard infusion in the treatment of malignancy. Methods: The 25 maligna...